A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
Completed · Phase 1 · Has a placebo group
Conditions studied: Herpes Zoster
In brief
The study will evaluate the safety, tolerability, and immunogenicity (your immune system's reaction) of the study vaccine called Herpes Zoster IN001 mRNA Vaccine (IN001) in healthy participants who are between 50 and 69 years of age
Key facts
- Study ID
- NCT06375512
- Run by
- Shenzhen Shenxin Biotechnology Co., Ltd
- People needed
- 150
- Starts
- 2024-07-05
- Expected to finish
- 2026-02-20
- Last updated by the study team
- 2026-03-31
Who can join
Age: 50 and older, up to 69. Sex: any. Healthy volunteers: accepted.
Where it is running
- CenExel — Hollywood, Florida, United States
- Emeritus Research Pty Ltd — Sydney, New South Wales, Australia
- Emeritus Research Pty Ltd — Melbourne, Victoria, Australia
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.